LGT Fund Management Co Ltd. Has $8.59 Million Stock Holdings in Stryker Corporation $SYK

LGT Fund Management Co Ltd. raised its position in Stryker Corporation (NYSE:SYK) by 170.7% during the 1st quarter, HoldingsChannel reports. The fund owned 26,137 shares of the medical technology company’s stock after buying an additional 16,483 shares during the quarter. LGT Fund Management Co Ltd.’s holdings in Stryker were worth $8,588,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in SYK. Norges Bank acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $1,822,272,000. Auto Owners Insurance Co grew its position in Stryker by 35,047.0% in the fourth quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock valued at $1,024,444,000 after purchasing an additional 2,906,448 shares in the last quarter. Wellington Management Group LLP grew its position in Stryker by 22.6% in the fourth quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock valued at $2,282,192,000 after purchasing an additional 1,198,665 shares in the last quarter. Corient Private Wealth LLC increased its stake in Stryker by 104.4% in the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after buying an additional 1,146,998 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after buying an additional 741,542 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Stock Performance

Stryker stock traded up $2.75 during midday trading on Friday, reaching $329.86. 2,724,614 shares of the company’s stock were exchanged, compared to its average volume of 2,471,298. The stock’s 50-day simple moving average is $310.12 and its 200 day simple moving average is $337.97. The firm has a market cap of $126.46 billion, a price-to-earnings ratio of 38.18, a P/E/G ratio of 2.11 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. The firm’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s dividend payout ratio is 40.74%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. UBS Group reduced their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Wells Fargo & Company decreased their price target on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. dropped their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Finally, Argus set a $370.00 target price on shares of Stryker in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $392.87.

Insider Buying and Selling at Stryker

In other Stryker news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares in the company, valued at $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 323,264 shares of company stock valued at $100,659,489 in the last three months. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.